Immunome, Inc. $IMNM Stock Sold by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. trimmed its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 31.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 621,079 shares of the company’s stock after selling 282,474 shares during the quarter. Nan Fung Trinity HK Ltd.’s holdings in Immunome were worth $13,359,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the stock. Allworth Financial LP acquired a new stake in Immunome during the 2nd quarter valued at approximately $25,000. Integrated Wealth Concepts LLC bought a new position in Immunome during the 2nd quarter worth approximately $27,000. KBC Group NV bought a new position in Immunome during the 1st quarter worth approximately $60,000. GK Wealth Management LLC bought a new position in Immunome during the 3rd quarter worth approximately $71,000. Finally, Sterling Capital Management LLC lifted its position in shares of Immunome by 840.0% in the 3rd quarter. Sterling Capital Management LLC now owns 3,478 shares of the company’s stock worth $75,000 after purchasing an additional 3,108 shares during the period. 44.58% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Jack Higgins sold 13,200 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the transaction, the insider owned 65,050 shares in the company, valued at $1,647,066. The trade was a 16.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.21% of the stock is owned by insiders.

Immunome Stock Performance

Shares of IMNM opened at $18.70 on Friday. Immunome, Inc. has a 52-week low of $16.11 and a 52-week high of $30.06. The business’s 50 day moving average price is $20.82 and its two-hundred day moving average price is $22.27. The firm has a market cap of $2.21 billion, a PE ratio of -7.08 and a beta of 2.68.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.14). Research analysts predict that Immunome, Inc. will post -2.59 EPS for the current fiscal year.

Analyst Ratings Changes

IMNM has been the topic of a number of analyst reports. Alliance Global Partners started coverage on shares of Immunome in a research note on Monday, September 21st. They issued a “buy” rating and a $32.00 price objective on the stock. William Blair assumed coverage on shares of Immunome in a research note on Friday, October 16th. They set an “outperform” rating for the company. HC Wainwright restated a “buy” rating on shares of Immunome in a report on Tuesday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Thursday, October 15th. Finally, Wedbush reaffirmed an “outperform” rating and set a $35.00 price target on shares of Immunome in a research report on Tuesday, October 27th. Fourteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.85.

Key Stories Impacting Immunome

These are some of the IMNM stories that stood out recently:

• Positive Sentiment: HC Wainwright kept its Buy rating despite reducing its estimates.
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to a loss of $0.76 from $0.68, and reduced full-year EPS estimates to losses of $2.64 for 2026, $2.71 for 2027, $2.41 for 2028, $1.63 for 2029, and $0.42 for 2030. The largest revisions include turning its 2029 forecast from a $0.40 profit to a loss, and its 2030 forecast from a $1.08 profit to a loss. These changes signal weaker expected earnings. Immunome analyst estimates
• Negative Sentiment: Piper Sandler cut its price target for Immunome. Piper Sandler price target cut

Immunome Profile

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.